[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100564203":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":24,"centralContacts":28,"locations":38,"responsibleParty":56,"collaborators":61,"id":63,"slug":24,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":64,"sex":70,"minAge":71,"maxAge":24,"enrollmentInfo":72,"targetDuration":24,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":84,"overallStatus":88,"whyStopped":24,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"University Medical Center Ho Chi Minh City (UMC)","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"LDL-C guided-LLT","ACTIVE_COMPARATOR","Patients in this group will receive treatment regimens adjusted accordingly to meet the LDL-C targets.",[13],"Other: LDL-C-guided-LLT",{"label":15,"type":16,"description":17,"interventionNames":18},"ApoB-guided-LLT","EXPERIMENTAL","Patients in this group will receive treatment regimens adjusted accordingly to meet the Apolipoprotein B targets.",[19],"Other: ApoB-guided-LLT",[21,25],{"type":6,"name":15,"description":22,"armGroupLabels":23,"otherNames":24},"Patients in this group will receive treatment regimens adjusted accordingly to meet the Apolipoprotein B targets",[15],null,{"type":6,"name":26,"description":11,"armGroupLabels":27,"otherNames":24},"LDL-C-guided-LLT",[9],[29,34],{"name":30,"role":31,"phone":32,"phoneExt":24,"email":33},"Vu Hoang Vu, Ph.D M.D","CONTACT","+84908431304","vu.vh@umc.edu.vn",{"name":35,"role":31,"phone":36,"phoneExt":24,"email":37},"Bao Thien Duong, M.D","+84936287137","bao.dt1@umc.edu.vn",[39],{"facility":40,"status":24,"city":41,"state":24,"zip":42,"country":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"University Medical Center Ho Chi Minh City","Ho Chi Minh City","700000","Vietnam",{"type":45,"coordinates":46},"Point",[47,48],106.62965,10.82302,{"lat":48,"lon":47},[51,53,55],{"name":30,"role":31,"phone":52,"phoneExt":24,"email":33},"+84‭908431304‬",{"name":35,"role":31,"phone":54,"phoneExt":24,"email":37},"+84‭936287137",{"name":30,"role":31,"phone":24,"phoneExt":24,"email":24},{"type":57,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":60,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","Vu Hoang Vu","Head of Interventional Cardiology Department, PhD MD","University of Medicine and Pharmacy at Ho Chi Minh City",[62],{"name":60,"class":6},"100564203",false,"NCT06626126","Efficacy of Lipid-Lowering Therapy Based on Apolipoprotein B Versus LDL-Cholesterol Levels in Patients Undergoing Percutaneous Coronary Intervention","Efficacy of Lipid-Lowering Therapy Based on Apolipoprotein B Versus LDL-Cholesterol Levels in Patients Undergoing Percutaneous Coronary Intervention: a Multicenter, Randomized Controlled Trial","ApoB-guidedLLT","Inclusion Criteria:\n\n1. Patients aged 18 years or older.\n2. Patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES).\n3. Patients who agree to participate and provide informed consent.\n\nExclusion Criteria:\n\n1. Inability to Provide Informed Consent: Patients who are unable or unwilling to provide consent.\n2. Limited life expectancy: patients with a life expectancy of less than 12 months due to other non-cardiac conditions.\n3. Liver Disease: patients with cirrhosis or significant liver dysfunction.\n4. Patients with contraindication to statin or other lipid-lowering therapy.\n5. Any condition that may interfere with the study process, including treatment adherence or follow-up appointments (e.g., dementia, alcohol abuse, severe debilitation, long distances required for follow-up, etc.).","ALL","18 Years",{"count":73,"type":74},1448,"ESTIMATED","INTERVENTIONAL",[77],"NA","This multicenter randomized trial is designed to assess the efficacy of lipid-lowering therapy in patients undergoing percutaneous coronary intervention, comparing an Apolipoprotein B-targeted approach with a Low-Density Lipoprotein Cholesterol (LDL-C)-targeted approach. The primary outcomes are to evaluate the proportion of patients achieving lipid-lowering treatment goals at the 1-year follow-up between the two treatment strategies: Apolipoprotein B-based therapy versus LDL-C-based therapy.",[80,81,82,83],"Coronary Arterial Disease (CAD)","Percutaneous Coronary Intervention","LDL-cholesterol","Lipid Metabolism Disorders",[68,85,86,87],"PCI","Coronary artery disease","lipid lowering therapy","NOT_YET_RECRUITING","2024-10-13",{"date":91,"type":92},"2024-10-16","ACTUAL",{"date":94,"type":74},"2025-01-01",{"date":96,"type":74},"2029-01-01",{"name":5,"class":6},1]